On 19 January, the EU Court of Justice made a ruling on the interpretation of EU regulations for products on the drug/device borderline that Erik Vollebregt, legal medtech expert and founding partner at Axon Lawyers (Netherlands), has criticized for placing a “negative burden of proof” on manufacturers.
The court’s ruling came about in light of two separate cases of nasal drops/sprays, referred to in the court document as Cases C‑495/21 and C‑496/21. Both cases took place...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?